Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs.
The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026.
Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 6, 26 | -0.60 Decreased by -62.16% | -0.58 Decreased by -2.56% |
| Nov 11, 25 | -0.55 Decreased by -7.84% | -0.80 Increased by +31.25% |
| Aug 12, 25 | -0.54 Decreased by -86.21% | -0.72 Increased by +25.00% |
| May 14, 25 | -0.68 Increased by +42.86% | -0.75 Increased by +9.33% |
| Mar 17, 25 | -0.37 Increased by +28.14% | -0.77 Increased by +51.95% |
| Nov 14, 24 | -0.51 | -0.75 Increased by +32.00% |
| Aug 15, 24 | -0.29 | -0.70 Increased by +58.57% |
| May 14, 24 | -1.19 | -0.78 Decreased by -52.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 3.91 M Decreased by -59.32% | -22.53 M Increased by +3.72% | Decreased by -576.02% Decreased by -136.68% |
| Sep 30, 25 | 8.66 M Decreased by -24.80% | -20.39 M Decreased by -8.63% | Decreased by -235.51% Decreased by -44.45% |
| Jun 30, 25 | 8.51 M Decreased by -57.45% | -19.91 M Decreased by -85.38% | Decreased by -233.85% Decreased by -335.70% |
| Mar 31, 25 | 4.13 M Decreased by -63.02% | -25.04 M Increased by +0.43% | Decreased by -606.71% Decreased by -169.22% |
| Dec 31, 24 | 9.61 M Decreased by -22.46% | -23.40 M Decreased by -21.27% | Decreased by -243.37% Decreased by -56.40% |
| Sep 30, 24 | 11.51 M Decreased by -6.87% | -18.77 M Increased by +5.28% | Decreased by -163.04% Decreased by -1.70% |
| Jun 30, 24 | 20.01 M Increased by +76.48% | -10.74 M Increased by +17.44% | Decreased by -53.67% Increased by +53.22% |
| Mar 31, 24 | 11.16 M Increased by +28.90% | -25.15 M Decreased by -55.88% | Decreased by -225.36% Decreased by -20.93% |